Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06724562 · ClinicalTrials.gov registry record
IL1 Inhibition in FOP
A clinical trial of Fibrodysplasia Ossificans Progressiva (FOP), sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 11
- Enrollment target
- 1
- Study location
NCT06724562 is a study of Fibrodysplasia Ossificans Progressiva (FOP) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06724562, a study of Fibrodysplasia Ossificans Progressiva (FOP), is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP. It will also generate key tools and preliminary data that are needed to design a future Phase II study. This study specifically focuses on patients with severe FOP who are being considered by their medical team for rescue therapy with anti-IL1 therapy. Preliminary data suggests patients experience significant decreases in flare frequency when taking anti-IL1 therapy, but other measures of efficacy remain unassessed, such as changes in heterotopic ossification formation, changes in pain medication use, and changes in functionality.
Conditions Studied
Interventions
- OTHER Anti-IL1 Therapy
Study Locations (1)
California
- UCSF - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06724562
The ClinicalTrials.gov registry entry for NCT06724562 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrodysplasia Ossificans Progressiva (FOP) appearing as the primary indexed condition, and to 1 intervention - of which Anti-IL1 Therapy is the first listed.
NCT06724562 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06724562 about?
NCT06724562 is a clinical study titled "IL1 Inhibition in FOP". This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP. It will also generate key tools and preliminary data that are needed to design a future Phase II...
What is the current status of trial NCT06724562?
This trial is currently recruiting. The enrollment target is 11 participants. The study started on 2025-04-01. Estimated completion is 2027-03.
What conditions does trial NCT06724562 study?
This clinical trial studies the following conditions: Fibrodysplasia Ossificans Progressiva (FOP).
What interventions are being tested in trial NCT06724562?
The interventions under investigation include: Anti-IL1 Therapy (OTHER).
Who is sponsoring clinical trial NCT06724562?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06724562 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrodysplasia Ossificans Progressiva (FOP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
RECRUITING · Phase 2
-
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.